Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Participants

In brief

The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants.

Key facts

Study ID

NCT04470778

Run by

Bristol-Myers Squibb

People needed

35

Starts

2020-07-20

Expected to finish

2021-03-28

Last updated by the study team

2025-02-06

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy participants having no clinically significant deviations from normal in medical history, physical examination (PE) findings, electrocardiograms (ECGs), vital signs, and clinical laboratory results that would compromise the ability to participate, complete, and/or interpret the results of the study
• Weight ≥ 50 kg and body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2 inclusive at screening
• Women and men must agree to follow specific methods of contraception, if applicable, while participating in the trial

You may not qualify if…

• Women who are pregnant or breastfeeding
• Any significant acute or chronic medical illness
• Any major surgery within 4 weeks of study treatment administration
• Any other sound medical, psychiatric, and/or social reason as determined by the investigator
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• ICON (LPRA) - Salt Lake — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.